|By Marketwired .||
|July 22, 2014 09:30 AM EDT||
BROSSARD, QUEBEC -- (Marketwired) -- 07/22/14 -- Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today a further expansion of the agreement first announced on November 26th 2013, with the first expansion announced on March 11, 2014, to further increase screening capacity in the country.
"Having announced a 100% expansion of our screening program in the UAE in November 2013, we are very pleased to announce an additional 75% expansion comprised by two contract extensions signed within a period of 8 months of the original agreement. Our client has seen a material impact on their business in the UAE and asked us for this increase to capture emerging market demand for their products and consequently for our services which are helping drive that demand. As a result of this expansion, the client will now have a total of 14 screening units operating across the UAE and will be able to pursue further opportunities with key health care providers in the country. We are very happy that our service is appreciated by the client and it is demonstrating a very positive impact on their bottom line, as evidenced by subsequent expansions of the program," said Peter Nowacki, Diagnos' Vice-President.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
About DIAGNOS Healthcare
DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
(450) 678-8882 ext 224